# Melanoma Aspirin is one of the more interesting repurposing candidates in **melanoma**. That is true for two different reasons. First, melanoma is highly **immunogenic**, which makes aspirin's effects on **PGE2**, **TXA2**, and immune escape especially relevant. Second, melanoma now has a real aspirin combination trial in advanced disease — and that trial taught an important lesson about **dose**. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) This is not yet a page with clear clinical proof of benefit. But it is one of the strongest pages for aspirin-immunotherapy logic. ### Overview Melanoma intersects with aspirin through three main pathways: * **COX-2 / PGE2-driven immune evasion** * **platelet TXA2-mediated metastatic shielding** * possible **immunotherapy potentiation** The prevention signal exists, but it is more modest than in colorectal cancer, endometrial cancer, or HCC. It also appears to be **sex-specific** and **duration-dependent**. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) The more important current story is therapeutic. Melanoma is one of the few aspirin cancer types with a melanoma-specific **Phase 2 immunotherapy-combination trial**. That makes it unusually relevant for readers already on checkpoint inhibitors. ### Key human data #### Prevention The prevention literature is supportive, but not fully consistent. * A 2024 meta-analysis found that regular aspirin use was associated with lower melanoma risk, with the strongest signal in **women**. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) * In **men**, the signal trended in the same direction in some datasets, but was less consistently statistically significant. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) * As in HCC and lung cancer, **duration matters**. The protective signal appears stronger after **5 years or more** of use. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) * Not all studies agree, and some reviews emphasise that melanoma prevention evidence remains less robust than the stronger aspirin-prevention pages. [Read the commentary](https://pmc.ncbi.nlm.nih.gov/articles/PMC11992038/) So the prevention story is real enough to mention, but not strong enough to oversell. #### The 2024 Phase 2 melanoma trial This is the most important melanoma-specific aspirin study so far. The trial enrolled **27 patients** with advanced or metastatic melanoma and tested **high-dose aspirin**, at **1,300 mg per day**, together with **pembrolizumab** and **ipilimumab**. The rationale came from strong preclinical work suggesting aspirin could improve immunotherapy response through **PGE2 suppression**. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) The main result was mixed. The addition of high-dose aspirin did **not** improve outcomes clearly in the full cohort compared with what would be expected from immunotherapy alone. Toxicity was also substantially higher, especially **GI toxicity**. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) But the trial also contained the most important lesson on the page. In the **per-protocol analysis**, patients who were able to stay on aspirin and complete induction showed improved survival compared with those who discontinued early. The authors concluded that the combination may still be promising, but that aspirin **dose** and toxicity management are critical. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) That creates a very specific next-step hypothesis: **high-dose aspirin was probably too toxic, and lower-dose aspirin may be the more rational combination strategy.** That low-dose hypothesis has not yet been properly tested in a melanoma trial. #### The 2025 Nature mechanism and melanoma The 2025 **Nature** paper on the **TXA2 → ARHGEF1 → CD8-positive T-cell suppression** axis used a **melanoma cell line** as one of its main experimental systems. That confirms the pathway is biologically active in melanoma. [Read the Nature paper](https://www.nature.com/articles/s41586-025-08626-7) An important commentary point also needs to stay visible. Some authors have noted that the strongest validation in that study came from the **lung-metastasis context**, and that robust melanoma-specific clinical benefit is still unproven. [Read the commentary](https://pmc.ncbi.nlm.nih.gov/articles/PMC11992038/) That is the right balance. The mechanism is present. The clinical translation in melanoma is still incomplete. ### Preclinical immunotherapy synergy The preclinical rationale for aspirin plus immunotherapy in melanoma is strong. Melanoma cells can produce **PGE2** through **COX-2**, and PGE2 acts as an immune-evasion signal. It can suppress dendritic-cell function, reduce effective T-cell priming, and help create a more immunosuppressive tumour environment. [Read the summary](https://www.pharmacytimes.com/view/aspirin-boosts-effectiveness-of-immunotherapy) Preclinical work from the **Francis Crick Institute** showed that aspirin plus immunotherapy reduced melanoma growth more than immunotherapy alone in mouse models. [Read the summary](https://www.pharmacytimes.com/view/aspirin-boosts-effectiveness-of-immunotherapy) This matters because aspirin may be removing **two separate immune brakes** at once: * **PGE2-mediated tumour immune suppression** * **TXA2-mediated platelet-supported immune evasion during metastasis** That combined logic is one of the strongest mechanistic arguments for aspirin in melanoma. ### Mechanistic relevance #### COX-2 and PGE2 immune evasion Melanoma commonly upregulates **COX-2** and produces **PGE2**. That matters because **PGE2** can: * impair dendritic-cell maturation * reduce effective T-cell priming * support **regulatory T-cell** expansion * weaken tumour immune infiltration Aspirin may help by reducing this PGE2 shield. [Read the summary](https://www.pharmacytimes.com/view/aspirin-boosts-effectiveness-of-immunotherapy) #### TXA2 and metastatic shielding Melanoma is highly capable of **haematogenous spread**. It often metastasises through the bloodstream to lung, liver, brain, and other sites. Platelet-assisted shielding of circulating melanoma cells is therefore highly relevant. [Read the review](https://www.sciencedirect.com/science/article/pii/S0031699725075180) The 2025 **Nature** mechanism work strengthens that logic because it directly connects **platelet-derived TXA2** to suppression of **CD8-positive T-cell killing**. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/40044852/) For the broader mechanism, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). #### BRAF and resistance biology About **half of melanomas** carry **BRAF V600** mutations. Because **COX-2 / PGE2** signalling can support resistance biology more broadly, aspirin may also have relevance in **BRAF inhibitor resistance**. That remains a mechanistic hypothesis rather than an established clinical use case. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) ### Clinical positioning | Setting | Evidence | Position | | ---------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------- | | **Prevention in women with longer-duration use** | Supportive meta-analytic signal, especially after **5 or more years**. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) | Modest but real | | **Prevention in men** | Signal is less consistent. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) | Not established | | **Advanced melanoma with high-dose aspirin plus dual ICI** | Phase 2 trial did not show clear overall benefit and caused high toxicity. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) | High-dose strategy not supported | | **Advanced melanoma with low-dose aspirin plus ICI** | Not yet properly tested in melanoma RCTs. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) | Important future-trial hypothesis | | **Preclinical immunotherapy synergy** | Strong mouse-model and mechanistic support. [Read the summary](https://www.pharmacytimes.com/view/aspirin-boosts-effectiveness-of-immunotherapy) | Strong biological rationale | | **BRAF-mutant resistance context** | Mechanistic plausibility only. [Read the Phase 2 paper](https://www.nature.com/articles/s44276-024-00057-7) | Investigational | | **TXA2 and the metastatic window** | Mechanistically present in melanoma models, but clinical significance remains uncertain. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/40044852/) | Biologically confirmed, clinically incomplete | ### Honest evidence assessment Melanoma sits in a very unusual place in this section. The **biology** is compelling. The **preclinical immunotherapy synergy** is strong. And unlike many pages, melanoma already has a disease-specific clinical trial. But that trial also taught the key lesson: **dose matters enough to make or break the result.** High-dose aspirin caused enough toxicity to prevent a clean answer. That does not kill the melanoma hypothesis. It refines it. The most important open question now is whether **low-dose aspirin** can preserve the immunologic benefit without the same toxicity burden. ### Practical interpretation This page is especially relevant for readers with melanoma who are: * already on **pembrolizumab**, **nivolumab**, **ipilimumab**, or combination checkpoint therapy * discussing metastatic risk or recurrent disease * known to have **BRAF-mutant** melanoma The most useful questions for the treating oncology team are: 1. Am I currently on checkpoint immunotherapy, and is there any rational discussion around **low-dose aspirin**, not high-dose aspirin? 2. What is my **BRAF** status, and is resistance biology part of the treatment discussion? 3. Does the Phase 2 trial mainly teach that the combination failed, or that the **dose was wrong**? 4. Are platelet count, clotting history, or metastatic pattern suggesting active platelet-supported disease biology? That is the most evidence-based way to use the melanoma aspirin literature right now. ### References * 2024 meta-analysis coverage — aspirin and melanoma prevention, strongest in women and with longer duration. [Read the summary](https://williamscancerinstitute.com/aspirin-melanoma-could-this-be-a-new-path-to-prevention/) * *npj Precision Oncology* 2024 — Phase 2 trial of aspirin with pembrolizumab and ipilimumab in advanced melanoma. [Read the paper](https://www.nature.com/articles/s44276-024-00057-7) * Francis Crick Institute coverage — aspirin improves immunotherapy effects in melanoma models. [Read the summary](https://www.pharmacytimes.com/view/aspirin-boosts-effectiveness-of-immunotherapy) * Melanoma Research Victoria summary — COX inhibition and immunotherapy reduce melanoma growth in mice. [Read the summary](https://melanomaresearchvic.com.au/adding-aspirin-to-cancer-immunotherapy-slows-tumor-growth-in-mice) * Yang et al., *Nature* 2025 — TXA2, ARHGEF1, and T-cell suppression, including melanoma-model relevance. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/40044852/) * 2025 commentary — melanoma-specific clinical evidence remains limited despite strong mechanism work. [Read the commentary](https://pmc.ncbi.nlm.nih.gov/articles/PMC11992038/) * 2025 review on platelet activation, aspirin, and cancer spread. [Read the review](https://www.sciencedirect.com/science/article/pii/S0031699725075180)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/melanoma.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.